cme.medlearning.de - CME Logo

Literaturverzeichnis

  • Andrews PL, Naylor RJ, Joss RA.
    Neuropharmacology of emesis and its relevance to antiemetic therapy. Supp Care Cancer 1998; 6: 197-203
  • Berger AM, Clark-Snow RA.
    Nausea and vomiting. De Vita VT, Hellman S, Rosenberg SA (eds). Cancer. Principles and practice of oncology, 6th edn. Philadelphia: Lippincott Williams & Wilkins 2001; 2869-2880
  • Bleiberg H.
    A new class of antiemetics: the NK1 receptor antagonists. Curr Opin Oncol 2000; 12: 284-288
  • Bokemeyer C.
    Aprepitant – Die Rolle des neuen NK1-Rezeptor-Antagonisten in der antiemetischen Therapie. Arzneimitteltherapie 2004; 22: 129-135
  • Caspar J, Aapro MS, Schmoll HJ.
    Richtlinien zur antiemtischen Therapie. Schmoll HJ, Höffken K, Possinger K (HRSG). Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie, Teil 1, 3. Aufl. Berlin: Springer 1999; 1489-1511
  • De Leon A.
    Palonosetron (Aloxi): a second-generation 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting. Baylor University Medical Center Proceedings 2006; 19: 413-416
  • Du Bois A, Feyer P, Ortner P.
    Emesis in der Tumortherapie. Hamburg: Ellyott Medizin Verlag, 1999
  • Edwards C, Carmichael J, Bayllis P, et al.
    Arginine vasopressin – a mediator of chemotherapy induced emesis? Br J Cancer 1989; 59: 467
  • Grunberg SM, Deusn RR, Mavros P, et al.
    Incidence of Chemotherapy-Induced Nausea and Emesis after Modern Antiemetics. Cancer 2004; 100; 2261-2268
  • Hesketh PJ, Kris MG, Grundberg SM, et al.
    Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-109
  • Hesketh PJ.
    Defining the emetogenicity of cancer chemotherapy regimes: Relevance to clinical practice. Oncologist 1999; 4: 191-196
  • Jakob A, Bokemeyer C, du Bois A.
    Antiemetische Therapie. Onkologe 2003; 9: 482-294
  • Koeller JM, AApro MS, Gralla RJ, et al.
    Antiemetic guidelines: crating a more practical treatment approach. Supportive Cancer Care 2002; 10: 519-522 2002
  • Link H, Bokemeyer C, Feyer P (Hrsg.)
    Supportivtherapie bei malignen Erkrankungen. Deutscher Ärzteverlag, Köln 2006. www.onkodin.de/zms/content/e6/e38842/e45084/index_ger.html
  • MASCC. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-28
  • MASCC. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Consensus Conference on antiemetic Therapy. Perugia, March 29-31, 2004